Pulse Biosciences Inc Common Stock (DE)
PLSE evidence brief
What we can confirm
- BioSniper Score:
- 9.8 / 10
- Market Cap:
- $3.48B
What it means
What to watch
Prepared research question
What matters most for PLSE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLSE
Pulse Biosciences Inc (PLSE) is a publicly traded biotechnology company developing a proprietary nano-pulse electric field (nsPFA) platform for non-thermal ablation in cardiac and thyroid applications, with its lead program in a pivotal atrial fibrillation trial.
Key risk: No product revenue
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$3.48B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Pulse Biosciences Inc (PLSE) is a publicly traded biotechnology company developing a proprietary nano-pulse electric field (nsPFA) platform for non-thermal ablation in cardiac and thyroid applications, with its lead program in a pivotal atrial fibrillation trial.
- Cash & equivalents of $101.6M as of 2026-06-30 [sec].
- Total revenue of $0.4M and net income of -$24.7M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $99.5M as of 2026-06-30 [sec].
- Surpassed enrollment midpoint of the NANOPULSE-AF pivotal clinical study for its nPulse Cardiac Catheter System as of July 29, 2026 [news].
- Completed patient enrollment in the PRECISE-BTN clinical study for benign thyroid nodules as of September 15, 2026 [news].
What works
- Strong cash position of $101.6M as of 2026-06-30, which management believes is sufficient to fund operations for at least twelve months [sec_mda].
- Rapid clinical progress: the NANOPULSE-AF trial began in April 2026 and surpassed its enrollment midpoint by July 2026 [news].
- Organizational realignment in March 2026 to focus on electrophysiology catheters for atrial fibrillation, following 'unprecedented clinical data' from a feasibility study [news].
What to weigh
- No revenue from product sales; net loss of -$24.7M for the period ending 2026-06-30 [sec].
- Heavy reliance on majority stockholder Robert Duggan for funding; he may not participate in future fundraisings [sec_mda].
- If cash resources become insufficient, the company may need to delay or scale back activities, including clinical trials [sec_mda].
- Stock has been described as 'pricey on book value' with high expectations from a 431.5% return over three years [news].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $101.6 million.”
SEC MD&A · August 6, 2026
Enrollment midpoint surpassed in NANOPULSE-AF trial
“On July 29, 2026, Pulse Biosciences, Inc. (the "Company") announced surpassing the enrollment midpoint of its NANOPULSE-AF clinical study”
News · July 29, 2026
Completion of enrollment in PRECISE-BTN study
“On September 15, 2026, Pulse Biosciences, Inc. (the "Company") announced completion of patient enrollment in its PRECISE-BTN clinical study”
News · September 15, 2026
Reliance on majority stockholder for funding
“Mr. Duggan may or may not elect to participate in any number of future fundraisings by the Company”
SEC MD&A · August 6, 2026
Risks & what to watch (3)›
Key risks
- No product revenue — Total revenue of $0.4M and net loss of -$24.7M as of 2026-06-30 [sec].
- Funding concentration risk — Majority stockholder Robert Duggan may not participate in future fundraisings [sec_mda].
- Clinical trial execution risk — If cash is insufficient, clinical trials may be discontinued [sec_mda].
What to watch
- Completion of NANOPULSE-AF pivotal trial and subsequent regulatory submissions [news].
- Results from the PRECISE-BTN thyroid nodule study after final follow-up [news].
- Any future fundraising or strategic partnership announcements [sec_mda].
- Cash burn rate relative to the $101.6M cash position [sec].
Sources: News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Pulse Biosciences Inc Common Stock (DE) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pulse Biosciences Inc Common Stock (DE) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.16
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
4 buys · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
96
Total value held
$167.3M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 1,339,778 | $28.9M |
| bank of america corp /de/ | 866,061 | $18.7M |
| vanguard capital management llc | 815,852 | $17.6M |
| portolan capital management, llc | 733,372 | $15.8M |
| geode capital management, llc | 491,946 | $10.6M |
| massachusetts financial services co /ma/ | 462,899 | $10.0M |
| state street corp | 456,927 | $9.9M |
| balyasny asset management l.p. | 265,164 | $5.7M |
| griffin asset management, inc. | 225,177 | $4.9M |
| lmr partners llp | 213,137 | $4.6M |
Showing top 10 of 96 institutional holders of Pulse Biosciences Inc Common Stock (DE). Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 16.2%
- Days to cover
- 11.2
- Shares short
- 2,915,409
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLSE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pulse Biosciences Inc Common Stock (DE)?
Pulse Biosciences Inc (PLSE) is a publicly traded biotechnology company developing a proprietary nano-pulse electric field (nsPFA) platform for non-thermal ablation in cardiac and thyroid applications, with its lead program in a pivotal atrial fibrillation trial.
Who is the CEO of Pulse Biosciences Inc Common Stock (DE)?
Mr. Paul Arthur LaViolette M.B.A. is the chief executive officer of Pulse Biosciences Inc Common Stock (DE) (PLSE).
Where is Pulse Biosciences Inc Common Stock (DE) headquartered?
Pulse Biosciences Inc Common Stock (DE) (PLSE) is headquartered in Miami, FL, United States.
What therapeutic areas does Pulse Biosciences Inc Common Stock (DE) focus on?
Pulse Biosciences Inc Common Stock (DE) develops therapies across Cardiovascular, Dermatology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.